228 / 330
228
28
TH
CONGRESS OF THE ESPU
08:48–08:51
S20-9 (PP)
BIOFEEDBACK AS SINGLE FIRST-LINE TREATMENT
FOR NON-NEUROPATHIC DYSFUNCTIONAL VOIDING
CHILDERN WITH DIURNAL ENURESIS
Tamer EWIDA
1
, Khalid FOUDA NEEL
1
, Hamdan ALHAZMI
2
, Mahmoud SALEM
TRBAY
1
, Mostafa ARAFA
1
, Moina TAHIR
1
and Fahad A. ALYAMI
3
1) King Saud University, King Saud University Medical city, Department of Surgery, Division of Urology, Riyadh, SAUDI
ARABIA - 2) King Saud University, King Saud University Medical city, Surgery, Division of Urology, Riyadh, SAUDI
ARABIA - 3) King Saud University, Department Of Surgery, Division of Urology, Riyadh, SAUDI ARABIA
PURPOSE
Non-neurogenic Dysfunctional Voiding (DV) accounts a significant portion of outpatient pediatric
urologist clinics patients. Biofeedback (BF) is a modern non-invasive promising modality treatment
for children with DV and daytime enuresis. Our objective is to investigate the efficacy of BF as
a single first-line treatment for DV children with diurnal enuresis.
MATERIAL AND METHODS
It is a retrospective cohort study, where data was obtained from prospectively maintained database
between January 2009 to March 2016. All children with non-neuropathic DV, and started BF as
first line treatment were included. Full urological history and physical examination, Dysfunctional
Voiding Symptom Score (DVSS), urine analysis, Ultrasound (US) and Uroflowmetery (UFM)+
Electromyogram (EMG) were recorded for all patients before and after finishing last BF cycle.
Patients satisfaction scale was collected.
RESULTS
Our sample comprised 61 patients, their mean age was 10 years (SD ±2.6), most of them (80.3%)
were females. When we analyzed the symptoms individually we found:52 patients (85.2%) com-
plained of diurnal enuresis, 16 (26.2%) of UTI, and 38 (62.3%) complained of voiding discomfort.
Six months after last BF cycle, there was a statistically significant objective improvement in US and
UFM+EMG findings, with disappearance of EMG signals in 40/61 (65.5%) patients, in addition to
the subjective symptomatic improvement as the mean DVSS decreases from 14 to 7.9 (p =0.003).
Forty-seven patients (77%) were satisfied, while only 8 patients (13.1%) were not satisfied.
CONCLUSIONS
BF could be considered as a potential effective single first-line treatment modality for children with
DV with diurnal enuresis.